A first-in-human Phase I study of the novel cancer stem cell (CSC) targeting antibody OMP-52M51 (anti-Notch1) administered intravenously to patients with certain advanced solid tumors.

被引：3
|
作者：
Davis, S. Lindsey [1 ]
LoRusso, Patricia [2 ]
Xu, Lu [3 ]
Kapoun, Ann M. [3 ]
Dupont, Jakob [3 ]
Munster, Pamela [4 ]
Eckhardt, S. Gail [1 ]
Patnaik, Amita [5 ]
机构：
[1] Univ Colorado Denver, Aurora, CO USA
[2] Karmanos Canc Inst, Detroit, MI USA
[3] OncoMed Pharmaceut Inc, Redwood City, CA USA
[4] Univ Calif San Francisco, San Francisco, CA 94143 USA
[5] START, San Antonio, TX USA
来源：
MOLECULAR CANCER THERAPEUTICS | 2013年 / 12卷 / 11期
关键词：
D O I：
10.1158/1535-7163.TARG-13-B48
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
B48
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Safety and early evidence of activity of a first-in-human phase I study of the novel cancer stem cell (CSC) targeting antibody OMP-52M51 (anti-Notch1) administered intravenously to patients with certain advanced solid tumors
    Patnaik, A.
    LoRusso, P.
    Munster, P.
    Tolcher, A. W.
    Davis, S. L.
    Heymach, J.
    Ferraroto, R.
    Xu, L.
    Kapoun, A. M.
    Faoro, L.
    Lewicki, J. A.
    Dupont, J.
    Eckhardt, S. G.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : 7 - 7
  • [2] Development and validation of a biomarker for prospective selection of Notch1 activation in patients with certain advanced solid tumors in a first-in-human phase1 study of the cancer stem cell targeting antibody OMP-52M51 (anti-Notch1)
    Cancilla, Belinda
    Tam, Raymond
    Zhang, Chun
    Anderson, Steve
    Lewicki, John
    Hoey, Tim
    McCune, Bryan
    Johnson, Lori
    Idusogie, Esohe
    Kapoun, Ann M.
    CANCER RESEARCH, 2015, 75
  • [3] Safety and Preliminary Efficacy Results of a Phase I First-in-Human Study of the Novel Notch-1 Targeting Antibody Brontictuzumab (OMP-52M51) Administered Intravenously to Patients with Hematologic Malignancies
    Casulo, Carla
    Ruan, Jia
    Dang, Nam H.
    Gore, Lia
    Diefenbach, Catherine
    Beaven, Anne W.
    Castro, Januario E.
    Porcu, Pierluigi
    Faoro, Leonardo
    Dupont, Jakob
    Kapoun, Ann
    Wang, Min
    McGuire, Kristin
    Flinn, Ian W.
    BLOOD, 2016, 128 (22)
  • [4] A first-in-human, phase I trial of the anti-DLL4 antibody (OMP-21M18) targeting cancer stem cells (CSC) in patients with advanced solid tumors
    Smith, D. C.
    Eisenberg, P.
    Stagg, R.
    Manikhas, G.
    Pavlovskiy, A.
    Sikic, B.
    Kapoun, A.
    Benner, S. E.
    EJC SUPPLEMENTS, 2010, 8 (07): : 73 - 73
  • [5] A first-in-human phase I study to evaluate the fully human monoclonal antibody OMP-59R5 (anti-Notch2/3) administered intravenously to patients with advanced solid tumors
    Tolcher, Anthony W.
    Chugh, Rashmi
    Chambers, Glenda
    Thorpe, Villette
    Dupont, Jakob
    Hill, Dawn
    Xu, Lu
    Kapoun, Ann
    Smith, David C.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [6] A First-in-human Phase I Study to Evaluate the Fully Human Monoclonal Antibody OMP-59R5 (anti-Notch2/3) Administered Intravenously to Patients with Advanced Solid Tumors
    Smith, D. C.
    Chugh, R.
    Patnaik, A.
    Papadopoulos, K.
    Chambers, G.
    Thorpe, V.
    Xu, L.
    Kapoun, A. M.
    Dupont, J.
    Tolcher, A.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : 11 - 12
  • [7] A first-in-human Phase 1 study of anti-cancer stem cell (CSC) agent OMP-54F28 (FZD8-Fc) targeting the WNT pathway in patients with advanced solid tumors.
    Smith, David C.
    Gordon, Michael
    Messersmith, Wells
    Chugh, Rashmi
    Mendelson, David
    Dupont, Jakob
    Stagg, Robert
    Kapoun, Ann M.
    Xu, Lu
    Brachmann, Rainer K.
    Jimeno, Antonio
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
  • [8] Anti-Notch1 antibody (OMP-52M51) impedes tumor growth and cancer stem cell frequency (CSC) in a chemo-refractory breast cancer xenograft model with an activating Notch1 mutation and screening for activated Notch1 across multiple solid tumor types.
    Cancilla, Belinda
    Cain, Jennifer
    Wang, Min
    Beviglia, Lucia
    Shah, Jalpa
    Gurney, Austin
    Lewicki, John
    Esserman, Laura
    Hoey, Tim
    Kapoun, Ann M.
    CANCER RESEARCH, 2013, 73 (08)
  • [9] A first-in-human phase I study to evaluate the fully human monoclonal antibody MNRP1685A (anti-NRP1) administered intravenously every three weeks in patients with advanced solid tumors.
    Weekes, C. D.
    Hegde, P.
    Xin, Y.
    Yu, R.
    Xiang, H.
    Beeram, M.
    Gore, L.
    Brachmann, R. K.
    Patnaik, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [10] A first-in-human study of the anti-α5β1 integrin monoclonal antibody PF-04605412 administered intravenously to patients with advanced solid tumors
    Mateo, J.
    Berlin, J.
    de Bono, J. S.
    Cohen, R. B.
    Keedy, V.
    Mugundu, G.
    Zhang, Lianglin
    Abbattista, A.
    Davis, C.
    Stampino, C. Gallo
    Borghaei, H.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 74 (05) : 1039 - 1046
12345